AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
前日終値
$37.11
+$0.98 · +2.71%
時間外
$37.85
+$0.74 · +1.99%
10月12日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
日中レンジ
現在 $37.11
52週レンジ
現在 $37.11
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
73
割安
センチメント
63
強気
リスク
44
やや高いリスク
モメンタム
74
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
日中レンジ
現在 $37.11
52週レンジ
現在 $37.11
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 2.25億 USD | 1.87億 USD | 1.59億 USD | 1.39億 USD | 1.27億 USD |
| 売上原価 | 5785.5万 USD | 4536.1万 USD | 3714.3万 USD | 2977.5万 USD | 2293.1万 USD |
| 粗利益 | 1.67億 USD | 1.42億 USD | 1.22億 USD | 1.09億 USD | 1.04億 USD |
| 研究開発 | 3288.5万 USD | 2776.7万 USD | 2733.9万 USD | 2562.7万 USD | 2417.7万 USD |
| 販売・一般管理 | 1.42億 USD | 1.17億 USD | 1.16億 USD | 1.13億 USD | 1.06億 USD |
| 営業費用 | 1.75億 USD | 1.45億 USD | 1.43億 USD | 1.39億 USD | 1.3億 USD |
| 支払利息 | 770.2万 USD | 820.6万 USD | 283.5万 USD | 62.4万 USD | 135.6万 USD |
| 減価償却費と償却費 | 819.3万 USD | 783.7万 USD | 555.3万 USD | 485.3万 USD | 474.1万 USD |
| 営業利益 | −784.9万 USD | −328.7万 USD | −2146.2万 USD | −2970.7万 USD | −2541.6万 USD |
| 純利益 | −1570.3万 USD | −996.4万 USD | −2171.6万 USD | −2894.8万 USD | −2698.5万 USD |
会社概要が更新されました 2026年10月13日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$53.17
上昇余地(43.28%)分割調整後の1株当たりの年間現金分配金。
$1.00
2010年(通年)+2296.8% 以来 1992
$0.0417
1,992
$0.06
2,005
$1.00
2,010
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2010年1月27日 | $1.00Special | 2010年1月29日 | 2010年2月12日 |
配当 | 2005年2月23日 | $0.06Special | — | — |
配当 | 1992年7月10日 | $0.0417Special | — | — |
配当落ち 2010年1月27日
$1.00
Special
2010年1月29日基準 · 支払日 2010年2月12日
配当落ち 2005年2月23日
$0.06
Special
配当落ち 1992年7月10日
$0.0417
Special
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI8123.7万0.00%2.3兆 USD0.03%$381.57-0.10%
iShares Russell 2000 ETFIWM5030.95万0.06%787.4億 USD0.19%$277.9-0.37%
Vanguard Extended Market ETFVXF3137.78万0.03%954億 USD0.05%$233.52-0.63%
iShares Russell 2000 Growth ETFIWO1765.05万0.13%139.17億 USD0.24%$353.71-0.86%
Vanguard Russell 2000 ETFVTWO1535.93万0.08%180億 USD0.06%$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA1147.86万0.05%218.24億 USD0.03%$32.66-0.40%
Fidelity Enhanced Small Cap ETFFESM1104.86万0.17%64.1億 USD0.28%$45.24-0.48%
iShares U.S. Medical Devices ETFIHI1048.89万0.29%35.74億 USD0.37%$52.79+2.03%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
Vanguard Russell 2000 ETFVTWO
Schwab U.S. Small-Cap ETFSCHA
Fidelity Enhanced Small Cap ETFFESM
iShares U.S. Medical Devices ETFIHIAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。